Who
John P. Hamill
SrVP/CFO/Prin Fin & Acct Ofcr
Company insider
Files Form 4 as: SrVP/CFO/Prin Fin & Acct Ofcr, Aprea Therapeutics; SVP & CFO, Windtree Therapeutics; VP Fin,Princ Fin&Acct Officer, Trevena.
In numbers
- Trades disclosed
- 39
- Buys
- 10
- Sells
- 0
- Bought
- $47K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 31 Aug 2018
- Last trade
- 31 Mar 2026
- Last filed
- 1 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Mar 2026filed 1 Apr 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $25K30,978 at $0.807 | filing |
| 31 Mar 2026filed 1 Apr 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —30,978 | filing |
| 31 Mar 2026filed 1 Apr 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $25K30,978 at $0.81 | filing |
| 31 Mar 2026filed 1 Apr 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —30,978 | filing |
| 12 Mar 2026filed 16 Mar 2026 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,095 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,380 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,380 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,095 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Bought | $5,0735,700 at $0.89 | filing |
| 30 Jan 2026filed 2 Feb 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —5,700 | filing |
| 30 Jan 2026filed 2 Feb 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —5,700 | filing |
| 30 Jan 2026filed 2 Feb 2026 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Bought | $5,0735,700 at $0.89 | filing |
| 10 Dec 2025filed 11 Dec 2025 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —5,000 | filing |
| 10 Dec 2025filed 11 Dec 2025 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Bought | $5,8505,000 at $1.17 | filing |
| 27 Mar 2025filed 31 Mar 2025 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,460 at $0.00 | filing |
| 27 Mar 2025filed 31 Mar 2025 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,365 at $0.00 | filing |
| 11 Oct 2024filed 16 Oct 2024 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Bought | $12350 at $2.46 | filing |
| 10 Oct 2024filed 15 Oct 2024 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,175450 at $2.61 | filing |
| 28 Mar 2024filed 28 Mar 2024 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,460 at $0.00 | filing |
| 28 Mar 2024filed 28 Mar 2024 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,365 at $0.00 | filing |
News
Reviewing Aprea Therapeutics (NASDAQ:APRE) & Oncobiologics (NASDAQ:OTLK)APRE · themarketsdaily.com · 20 Oct 2026Reviewing Aprea Therapeutics (NASDAQ:APRE) & CRISPR Therapeutics (NASDAQ:CRSP)APRE · tickerreport.com · 12 Oct 2026
0 headlines in the last 90 days name John P. Hamill; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.